市場調査レポート

コンパニオン診断の世界市場:乳癌、肺癌、結腸直腸癌、胃癌、黒色腫、その他の癌市場の分析、規模、シェア、成長、動向、見通し

Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

発行 Transparency Market Research 商品コード 279441
出版日 ページ情報 英文 84 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
コンパニオン診断の世界市場:乳癌、肺癌、結腸直腸癌、胃癌、黒色腫、その他の癌市場の分析、規模、シェア、成長、動向、見通し Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
出版日: 2013年08月29日 ページ情報: 英文 84 Pages
概要

当レポートでは、世界のコンパニオン診断市場について調査分析を行い、市場概要、2013年〜2019年の市場予測、適応症別概要、地域別市場の概要、シェア分析、主要企業などについてまとめ、概略下記の構成で取り上げております。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • イントロダクション
  • 市場促進因子
  • 市場抑制因子
  • 市場機会
  • ファイブフォース分析:世界のコンパニオン診断市場
  • 市場魅力分析:世界のコンパニオン診断市場:地域別:2012年

第4章 コンパニオン診断市場:適応症別

  • イントロダクション
    • 比較分析
    • 乳癌
    • 肺癌
    • 結腸直腸癌
    • 胃癌
    • 黒色腫
    • その他(HIV、サラセミア)

第5章 コンパニオン診断市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • 世界のその他の諸国

第6章 競合状況

  • 主要企業市場シェア:2012年

第7章 提案

  • 製薬会社/診断企業のビジネスモデルの変化
  • 新興市場への投資

第8章 企業プロファイル

  • Abbott Laboratories
  • Agendia N.V.
  • Agilent Technologies, Inc.,
  • Biogenex Laboratories, Inc.
  • Ge Healthcare Ltd.
  • Genomic Health, Inc.
  • Laboratory Corporation Of America Holdings (Labcorp)
  • Life Technologies Corporation
  • Qiagen N.V.
  • Resonance Health Analysis Services Pty Ltd.
  • Roche Holdings Ag
  • Siemens Healthcare

図表

目次

This report studies the global market for companion diagnostics from two perspectives - companion diagnostics by indication and by geography. The market for companion diagnostics by indication includes sub-segments such as breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma and others (HIV, Thalassemia). By geography, the companion diagnostics market has been divided into four regions, namely, North America, Europe, Asia-Pacific and RoW. Market size and forecast for each segment and sub-segment has been provided for the period 2011 to 2019 in terms of USD million, with 2012 as the base year. The compounded annual growth rate (CAGR) for each market segment has been provided for the forecast period (2013 to 2019).

The report also contains a section on market overview which consists of a detailed qualitative analysis of various market dynamics, such as drivers, restraints and opportunities. A section on market attractiveness analysis and Porter's five force analysis for the companion diagnostics market has also been included.

Market share analysis of the leading players operating in the companion diagnostics market, in terms of % share for the year 2012, has been presented in the competitive landscape. The report also includes the list of recommendations for new market entrants. Some of the key market players profiled in this report include Roche Holdings AG, Abbott Laboratories, Genomic Health, Inc., Qiagen N.V., Life Technologies Corporation, Agilent Technologies, Inc. and GE Healthcare, Ltd.

The global companion diagnostics market is segmented into the following categories:

Companion Diagnostics Market, by Indications

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Melanoma
  • Other (HIV, Thalassemia)

Companion Diagnostics Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Table of Contents

Chapter 1 - Introduction

  • 1.1. Report Description
  • 1.2. Research Methodology
  • 1.3. Market Segmentation
  • 1.4. List Of Abbreviations

Chapter 2 - Executive Summary

Chapter 3 - Market Overview

  • 3.1. Introduction
  • 3.2. Market Drivers
    • 3.2.1. Rising Need For Companion Diagnostics Along With Targeted Therapies
    • 3.2.2. Increasing Demand As Well As Developmental Efforts Towards Personalized Medicine
    • 3.2.3. The Pharmacoeconomic Advantage: Reduced Drug Development Costs
    • 3.2.4. Increasing Cancer Incidence Worldwide
    • 3.2.5. Impact Analysis Of Market Drivers
  • 3.3. Market Restraints
    • 3.3.1. Effect Of Influence Of Advocacy Groups And Clinical Societies
    • 3.3.2. Prolonged Developmental And Approval Phases
    • 3.3.3. Impact Analysis Of Market Restraints
  • 3.4. Market Opportunities
    • 3.4.1. Expansion Into Newer Indication Areas
  • 3.5. Porter's Five Force Analysis: Global Companion Diagnostics Market
    • 3.5.1. Bargaining Power Of Buyers
    • 3.5.2. Bargaining Power Of Suppliers
    • 3.5.3. Threat Of Substitutes
    • 3.5.4. Threat Of New Entrants
    • 3.5.5. Competitive Rivalry
  • 3.6. Market Attractiveness Analysis: Global Companion Diagnostics Market, By Geography, 2012

Chapter 4 - Companion Diagnostics Market, By Indications, 2011 - 2019 (USD Million)

  • 4.1. Introduction
    • 4.1.1. Comparative Analysis: Global Companion Diagnostics Market, By Indication, 2012 & 2019 (Value %)
    • 4.1.2. Breast Cancer
    • 4.1.3. Lung Cancer
    • 4.1.4. Colorectal Cancer
    • 4.1.5. Gastric Cancer
    • 4.1.6. Melanoma
    • 4.1.7. Others (HIV, Thalassemia)

Chapter 5 - Companion Diagnostics Market, By Geography, 2011 - 2019 (USD Million)

  • 5.1. Overview
    • 5.1.1. Comparative Analysis: Global Companion Diagnostics Market, By Geography, 2012 & 2019 (Value %)
  • 5.2. North America
    • 5.2.1. North America Companion Diagnostics Market Size And Forecast, 2011 - 2019 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Companion Diagnostics Market Size And Forecast, 2011 - 2019 (Usd Million)
  • 5.4. Asia-Pacific
    • 5.4.1. Asia-Pacific Companion Diagnostics Market Size And Forecast, 2011 - 2019 (USD Million)
  • 5.5. Rest Of The World (Row)
    • 5.5.1. Row Companion Diagnostics Market Size And Forecast, 2011 - 2019 (USD Million)

Chapter 6 - Competitive Landscape

  • 6.1. Market Share By Key Players, 2012 (%)

Chapter 7 - Recommendations

  • 7.1. Changing Business Models of Pharmaceutical and Diagnostics Manufacturers
  • 7.2. Investing in Emerging Economies

Chapter 8 - Company Profiles

  • 8.1. Abbott Laboratories
    • 8.1.1. Company Overview
    • 8.1.2. Financial Overview
    • 8.1.3. Product Portfolio
    • 8.1.4. Business Strategies
    • 8.1.5. Recent Developments
  • 8.2. Agendia N.V.
    • 8.2.1. Company Overview
    • 8.2.2. Product Portfolio
    • 8.2.3. Business Strategies
    • 8.2.4. Recent Developments
  • 8.3. Agilent Technologies, Inc.,
    • 8.3.1. Company Overview
    • 8.3.2. Financial Overview
    • 8.3.3. Product Portfolio
    • 8.3.4. Business Strategies
    • 8.3.5. Recent Developments
  • 8.4. Biogenex Laboratories, Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Product Portfolio
    • 8.4.3. Business Strategies
    • 8.4.4. Recent Developments
  • 8.5. Ge Healthcare Ltd.
    • 8.5.1. Company Overview
    • 8.5.2. Financial Overview
    • 8.5.3. Product Portfolio
    • 8.5.4. Business Strategies
    • 8.5.5. Recent Developments
  • 8.6. Genomic Health, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Financial Overview
    • 8.6.3. Product Portfolio
    • 8.6.4. Business Strategies
    • 8.6.5. Recent Developments
  • 8.7. Laboratory Corporation Of America Holdings (Labcorp)
    • 8.7.1. Company Overview
    • 8.7.2. Financial Overview
    • 8.7.3. Product Portfolio
    • 8.7.4. Business Strategies
    • 8.7.5. Recent Developments
  • 8.8. Life Technologies Corporation
    • 8.8.1. Company Overview
    • 8.8.2. Financial Overview
    • 8.8.3. Product Portfolio
    • 8.8.4. Business Strategies
    • 8.8.5. Recent Developments
  • 8.9. Qiagen N.V.
    • 8.9.1. Company Overview
    • 8.9.2. Financial Overview
    • 8.9.3. Product Portfolio
    • 8.9.4. Business Strategies
    • 8.9.5. Recent Developments
  • 8.10. Resonance Health Analysis Services Pty Ltd.
    • 8.10.1. Company Overview
    • 8.10.2. Product Portfolio
    • 8.10.3. Business Strategies
    • 8.10.4. Recent Developments
  • 8.11. Roche Holdings Ag
    • 8.11.1. Company Overview
    • 8.11.2. Financial Overview
    • 8.11.3. Product Portfolio
    • 8.11.4. Business Strategies
    • 8.11.5. Recent Developments
  • 8.12. Siemens Healthcare
    • 8.12.1. Company Overview
    • 8.12.2. Financial Overview
    • 8.12.3. Product Portfolio
    • 8.12.4. Business Strategies
    • 8.12.5. Recent Developments

List of Figures

  • FIG. 1: Companion Diagnostics Market Segmentation
  • FIG. 2: Global Companion Diagnostics Market, by Indication, 2012 (USD Million)
  • FIG. 3: Porter's Five Force Analysis: Global Companion Diagnostics Market
  • FIG. 4: Market Attractiveness Analysis: Global Companion Diagnostics Market, by Geography, 2012
  • FIG. 5: Comparative Analysis: Global Companion Diagnostics Market, by Indications, 2012 & 2019 (Value %)
  • FIG. 6: Global Breast Cancer Companion Diagnostics Market, Size and Forecast, 2011-2019 (USD Million)
  • FIG. 7: Global Lung Cancer Companion Diagnostics Market, Size and Forecast, 2011-2019 (USD Million)
  • FIG. 8: Global Colorectal Cancer Companion Diagnostics Market, Size and Forecast, 2011-2019 (USD Million)
  • FIG. 9: Global Gastric Cancer Companion Diagnostics Market, Size and Forecast, 2011-2019 (USD Million)
  • FIG. 10: Global Melanoma Companion Diagnostics Market, Size and Forecast, 2011-2019 (USD Million)
  • FIG. 11: Global Other Companion Diagnostics Market, Size and Forecast, 2011-2019 (USD Million)
  • FIG. 12: Comparative Analysis: Global Companion Diagnostics Market, by Geography, 2012 & 2019 (Value %)
  • FIG. 13: North American Market for Companion Diagnostics, Size and Forecast, 2011-2019 (USD Million)
  • FIG. 14: European Market for Companion Diagnostics, Size and Forecast, 2011- 2019 (USD Million)
  • FIG. 15: Asia-Pacific Market for Companion Diagnostics, Size and Forecast, 2011-2019 (USD Million)
  • FIG. 16: RoW Market for Companion Diagnostics, Size and Forecast, 2011-2019 (USD Million)
  • FIG. 17: Market Share Analysis: Companion Diagnostics Market, 2012 (%)
  • FIG. 18: Annual Revenues: Abbott Laboratories, 2010-2012 (USD Million)
  • FIG. 19: Annual Revenues: Agilent Technologies, Inc., 2010-2012 (USD Million)
  • FIG. 20: Annual Revenues: GE Healthcare, 2010-2012 (USD Million)
  • FIG. 21: Annual Revenues: Genomic Health, Inc., 2010-2012 (USD Million)
  • FIG. 22: Annual Revenues: LabCorp, 2010-2012 (USD Million)
  • FIG. 23: Annual Revenues: Life Technologies Corporation, 2010-2012 (USD Million)
  • FIG. 24: Annual Sales: Qiagen N.V., 2010-2012 (USD Million)
  • FIG. 25: Annual Revenues: Roche Holdings AG, 2010-2012 (USD Million) (1Swiss Franc = 1.09 USD) (USD Million)
  • FIG. 26: Annual Revenues: Siemens Healthcare, 2010-2012 (USD Million)

List of Tables

  • TABLE 1: List of Abbreviations
  • TABLE 2: Market Snapshot: Global Companion Diagnostics Market
  • TABLE 3: Impact Analysis of Market Drivers
  • TABLE 4: Impact Analysis of Market Restraints
  • TABLE 5: Global Companion Diagnostics Market, by Indications, Size and Forecast, 2011 - 2019 (USD Million)
  • TABLE 6: Global Companion Diagnostics Market, by Geography, Size and Forecast, 2011 - 2019 (USD Million)
Back to Top